Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.65 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122158 | 0.99 | EGFR (0.64) | EGFRFBP1ERBB2ERBB4HDAC3 | |
| SCHEMBL5117581 | 0.99 | EGFR (0.64) | EGFRFBP1ERBB2ERBB4HDAC3 | |
| SCHEMBL5108991 | 0.92 | EGFR (0.63) | EGFRFBP1ERBB2ERBB4HDAC3 | |
| SCHEMBL5115993 | 0.92 | EGFR (0.63) | EGFRFBP1ERBB2ERBB4HDAC3 | |
| SCHEMBL5116516 | 0.92 | EGFR (0.63) | EGFRFBP1ERBB2ERBB4HDAC3 | |
| SCHEMBL5121864 | 0.91 | EGFR (0.61) | EGFRFBP1ERBB2ERBB4HDAC3 | |
| SCHEMBL5108725 | 0.90 | EGFR (0.65) | EGFRFBP1ERBB2ERBB4HDAC3 | |
| SCHEMBL5111430 | 0.90 | EGFR (0.61) | EGFRFBP1ERBB2ERBB4HDAC3 | |
| SCHEMBL5122598 | 0.90 | EGFR (0.61) | EGFRFBP1ERBB2ERBB4HDAC3 | |
| SCHEMBL5112366 | 0.89 | EGFR (0.64) | EGFRFBP1ERBB2ERBB4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461166-B2 | Anilinoquinazolinyl amide derivatives; radiolabels as bioprobes for Positron Emission Tomography and Single Photon Emission Computed Tomography, and as radiopharmaceuticals for radiotherapy; improved solubility, bioavailability, biostability | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2013-06-11 | — | — | US | disclosed |
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | T.K. SIGNAL LTD. (IL) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | EGFR, TK1, ERBB2 | EGFR 1/4885FBP1 1341/4885ERBB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.